Y-39983

01/01/2013 - "The inhibitory effect of Y-39983 on demyelination is probably due to the inactivation of ROCK substrates, which are important for neurite outgrowth, growth cone collapse and demyelination of oligodendrocytes."
01/01/2013 - "The inhibition of demyelination by Y-39983 was confirmed by solochrome cyanine staining and electron microscopy. "
01/01/2013 - "We investigated the protective effect of a specific ROCK inhibitor, Y-39983, on demyelination and axonal damage in chronic EAE. "
01/01/2013 - "Y-39983, a selective Rho-kinase inhibitor, attenuates experimental autoimmune encephalomyelitis via inhibition of demyelination."
01/01/2013 - "To further study the effect of Y-39983 on demyelination in EAE, we tested three major ROCK substrates, including myosin light chain phosphorylation, LIMK2 and collapsin response mediator protein-2. "

04/01/2005 - "ROCK inhibitor Y-39983 might be a candidate drug for lowering IOP by increasing conventional outflow and producing fewer side effects on accommodation and miosis."

08/01/2015 - "Efficacy and safety of SNJ-1656 in primary open-angle glaucoma or ocular hypertension."

02/18/2014 - "The degree of hyperemia was significantly lower in rabbits treated with AMA0076 then with Y-39983. "
02/18/2014 - "Hyperemia after single topical dosing of AMA0076 and Y-39983 was scored. "

07/01/2007 - "In monkeys, at 3 hours after topical administration of 0.05% Y-39983, maximum reduction of IOP was 2.5 +/- 0.8 mm Hg. No serious side effects were observed in ocular tissues except sporadic punctate subconjunctival hemorrhage during long-term topical administration of Y-39983 four times a day (at 2-hour intervals) in rabbits or monkeys. "